Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 20, 2021 06:30 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business Highlights and Second Quarter 2021 Financial Results

New Data Supporting Potential of ADG20 for Both the Treatment and Prevention of COVID-19 to be Presented at IDWeek 2021 Patient Population in Global EVADE Phase 2/3 Clinical Trial of ADG20 Expanded...
September 10, 2021 17:12 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics anuncia expansión de población de pacientes en ensayo clínico global de Fase 2/3 de ADG20 para la prevención de COVID-19

WALTHAM, Massachusetts, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., una empresa biofarmacéutica de etapa clínica centrada en el descubrimiento, desarrollo y comercialización de...
September 10, 2021 17:12 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics, ADG20의 코로나19 예방 능력에 대한 글로벌 임상 2/3상 참여 환자 대상 확대

미국 매사추세츠주 월섬, Sept. 11, 2021 (GLOBE NEWSWIRE) -- 임상 단계 바이오 제약사로 팬데믹으로 번질 우려가 있는 감염병 치료를 위한 항체 기반 솔루션 발견, 개발, 상용화에 중점을 두고 있는 Adagio Therapeutics, Inc.는 코로나19 예방용 ADG20의 EVADE 임상2/3상 시험을 위한 독립 데이터...
September 10, 2021 17:12 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics宣布在全球2/3期ADG20预防新冠肺炎临床试验中扩大患者群体

马萨诸塞州沃尔瑟姆, Sept. 11, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics,...
September 10, 2021 17:12 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics annonce l'élargissement de la population de patients participant à l'essai clinique mondial de phase 2/3 de l'ADG20 pour la prévention de la COVID-19

WALTHAM, Massachusetts, 10 sept. 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., une société biopharmaceutique au stade clinique axée sur la découverte, le développement et la commercialisation...
September 10, 2021 17:12 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics kündigt Ausweitung der Patientenpopulation in der globalen klinischen Phase-II/III-Studie zu ADG20 für die COVID-19-Prävention an

WALTHAM, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., ein biopharmazeutisches Unternehmen im Bereich der klinischen Forschung, das sich auf die Erforschung, Entwicklung und...
September 10, 2021 17:12 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics Anuncia Expansão da População de Pacientes no Ensaio Clínico Global de Fase 2/3 do ADG20 para Prevenção da COVID-19

WALTHAM, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) -- A Adagio Therapeutics, Inc., uma empresa biofarmacêutica de estágio clínico focada na descoberta, desenvolvimento e comercialização de soluções...
September 10, 2021 17:12 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics Mengumumkan Perluasan Populasi Pesakit dalam Percubaan Klinikal Fasa 2/3 Global bagi ADG20 untuk Pencegahan COVID-19

WALTHAM, Mass., Sept. 11, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., syarikat biofarmaseutikal peringkat klinikal yang berfokus pada penemuan, pembangunan dan pengkomersialan penyelesaian...
September 10, 2021 17:12 ET | Source: Adagio Therapeutics, Inc.

アダジオ･セラピューティクス、新型コロナウイルス感染症予防薬ADG20の第2/3相臨床試験で世界的に患者集団の拡張を発表

マサチューセッツ州ウォルサム発, Sept. 11, 2021 (GLOBE NEWSWIRE) -- パンデミックの可能性がある感染症用に抗体ベースのソリューションの創薬、開発、販売を主な事業とする臨床用バイオ医薬品企業であるアダジオ･セラピューティクス (Adagio Therapeutics)...
September 10, 2021 17:12 ET | Source: Adagio Therapeutics, Inc.

Adagio Therapeutics 宣佈在全球第 2/3 期 ADG20 預防 2019 冠狀病毒病臨床試驗中擴大患者人口

麻省沃爾瑟姆, Sept. 11, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. 是一家臨床階段生物製藥公司，專門發現、開發及商業化具有疫情潛力的傳染病抗體解決方案，今天宣佈關於使用 ADG20 預防 2019 冠狀病毒病的 EVADE 第 2/3 期試驗的獨立數據監測委員會 (IDMC) 剛提出一項建議，將擴大第 3...